Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, ...
Kinder Morgan (KMI) closed the latest trading day at $28.16, indicating a -0.46% change from the previous session's end. The stock exceeded the S&P 500, which registered a loss of 1.54% for the day.